It has been revealed that the presence of circulating tumour DNA (ctDNA) in early-stage triple-negative breast cancer can aid in independently predicting the risk of recurrence of the disease in patients who had undergone surgery after neoadjuvant chemotherapy. This may represent an important novel stratification factor for future post-neoadjuvant trials.
Patients with triple-negative breast cancer with residual disease have an exceptionally high risk of recurrence and novel therapies and technologies are thus essential, including those that can potentially predict the risk of relapse. ctDNA or plasma-derived tumour DNA is being explored as a way to detect cancer, guide treatment, and monitor patients during remission as the presence of ctDNA can signal the presence of cancer.
Researchers analysed plasma samples collected from 196 patients enrolled in the BRE12-158 clinical trial, which studied genomically directed therapy versus physician’s choice ...
Please login to read the full text of the article.
If you have no account yet, please register now.
« No added benefit for doxorubicin + docetaxel vs doxorubicin + cyclophosphamide Next Article
Palbociclib not statistically superior to capecitabine in PFS »